In its third quarter ended October 30, 2025, Kimberly-Clark reported adjusted earnings per share of $1.82, beating consensus by $0.07, while revenue held flat year-over-year at $4.15 billion, $50 million above estimates. Organic sales rose 2.5%, driven by a 2.4% volume increase despite a 2.2% drag from exiting the U.S. private-label diaper business. Adjusted gross margin of 36.8% was down 170 basis points, as productivity gains were outweighed by higher input costs and tariff impacts. These results underscore the resilience of KMB’s personal care and consumer tissue franchises, supporting its investment thesis of stable cash flow generation.

Kimberly-Clark announced a definitive agreement to acquire Kenvue for $48.7 billion in a combined cash and stock transaction. Kenvue, the consumer health spin-off of a major pharmaceutical group, complements KMB’s existing Personal Care portfolio—home to Huggies, Kotex and Depend—by adding leading global brands in over-the-counter medicines and skincare. Management projects that the deal will enhance scale synergies, expand geographic reach in over 175 markets, and accelerate earnings per share accretion beginning in year two post-close.

KMB has increased its dividend for 53 consecutive years, yielding approximately 5.1%, well above the S&P 500 average. The company’s 85% payout ratio reflects management’s confidence in cash flow stability. Institutional filings show that Vanguard Group holds 40.4 million shares (up 14.8% in Q2), Charles Schwab Investment Management owns 11.5 million shares (up 1.9%), and Geode Capital holds 8.3 million shares (up 4.6%). Allspring Global Investments reduced its stake by 49.1% to 22,001 shares, signaling some profit-taking ahead of the Kenvue close but overall positioning remains heavily institutional at over 76% ownership.